Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study

被引：0
|
作者：
Zhang, Yong
Che, Shaomin
Chen, Nanzheng
Li, Xinju
Fu, Junke
Yu, Chenao
Wang, Tianren
Liang, Runjia
Xu, Haozhen
Wu, Qifei
Jia, Zhuoqi
Zhu, Cailin
Gong, Tuotuo
Li, Haijun
Zhang, Boxiang
Hu, Yunyun
Liu, Yaqi
机构：
[1] Xi An Jiao Tong Univ, Dept Thorac Surg, Affiliated Hosp 1, Xian, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Radiat Oncol, Affiliated Hosp 1, Xian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16090
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)
    Yan, Xiaolong
    Duan, Hongtao
    Ni, Yunfeng
    Zhou, Yongan
    Wang, Xiaoping
    Qi, Haini
    Gong, Li
    Liu, Honggang
    Tian, Feng
    Lu, Qiang
    Sun, Jianyong
    Yang, Ende
    Zhong, Daixing
    Wang, Tao
    Huang, Lijun
    Wang, Jian
    Wang, Chaoyang
    Wang, Yuanyong
    Wan, Zhiyi
    Lei, Jie
    Zhao, Jinbo
    Jiang, Tao
    INTERNATIONAL JOURNAL OF SURGERY, 2022, 103
  • [12] Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
    Yang, Weixiong
    Xing, Xiangbin
    Yeung, Sai-Ching Jim
    Wang, Siyu
    Chen, Wenfang
    Bao, Yong
    Wang, Fang
    Feng, Shiting
    Peng, Fang
    Wang, Xiaoyan
    Chen, Shuling
    He, Minghui
    Zhang, Ning
    Wang, Honglei
    Zeng, Bo
    Liu, Zhenguo
    Kidane, Biniam
    Seder, Christopher W.
    Koyanagi, Kazuo
    Shargall, Yaron
    Luo, Honghe
    Peng, Sui
    Cheng, Chao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [13] Comment on 'Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)'
    Cao, Meili
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (04) : 1060 - 1061
  • [14] Treg cells and the response to neoadjuvant chemotherapy combined with immunotherapy in resectable esophageal squamous carcinoma
    Jiang, Bo
    Yang, Xin
    Yu, Pengyi
    Zhang, Chu
    Li, Chunyang
    Tang, Wenhua
    Zhang, Junling
    Huang, Mengli
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [15] Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
    Dong, Y.
    Luo, J.
    Liu, S.
    Han, H.
    Lin, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S866 - S866
  • [16] Tislelizumab plus chemotherapy for esophageal squamous cell carcinoma
    Andres, Ulrike
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (11):
  • [17] A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma
    Li, Xiaodong
    Xu, Congcong
    Qiu, Hongbin
    Chen, Dong
    Zhu, Kanghao
    Zhang, Bo
    Zhang, Jian
    Xu, Anyi
    Wang, Chunguo
    Shen, Jianfei
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (05)
  • [18] Tislelizumab (TIS) plus chemotherapy (Chemo)/ chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
    Chen, L.
    Liao, Y.
    Jiang, T.
    Kang, M.
    Mei, X.
    Tan, L.
    Liu, J.
    Zhang, Z.
    Yu, W.
    Li, L.
    Jiang, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1529 - S1529
  • [19] Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: A single-arm, phase II trial
    Wu, Wenjie
    Yao, Jie
    Zhang, Tong
    Zhang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [20] Tislelizumab plus chemotherapy sequential neochemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
    He, W.
    Wang, C.
    Wu, L.
    Wan, G.
    Han, Y.
    Leng, X.
    Wang, Q.
    Peng, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S860 - S860
12345